Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.00 USD
Change Today +0.41 / 11.42%
Volume 18.9K
EVAR On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GM
As of 5:20 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

lombard medical inc (EVAR) Snapshot

Open
$3.82
Previous Close
$3.59
Day High
$4.15
Day Low
$3.70
52 Week High
04/25/14 - $11.34
52 Week Low
03/26/15 - $3.59
Market Cap
64.7M
Average Volume 10 Days
26.0K
EPS TTM
--
Shares Outstanding
16.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LOMBARD MEDICAL INC (EVAR)

Related News

No related news articles were found.

lombard medical inc (EVAR) Related Businessweek News

No Related Businessweek News Found

lombard medical inc (EVAR) Details

Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, and internationally. The company’s principal product is Aorfix, which is an endovascular stent-graft for the treatment of an abdominal aortic aneurysm with angulation at the neck of the aneurysm of up to 90 degrees. It is also developing stent-graft system to treat thoracic aortic aneurysms. Lombard Medical sells its products directly through its direct sales force and third-party distributors. The company was founded in 2000 and is based in Didcot, United Kingdom.

lombard medical inc (EVAR) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

lombard medical inc (EVAR) Key Developments

Lombard Medical, Inc. Receives Approval for the AorFlex Delivery System from the Japanese Ministry of Health, Labour and Welfare

Lombard Medical, Inc. announced that it has received approval for the AorFlex delivery system from the Japanese Ministry of Health, Labour and Welfare. Commercial sales will follow reimbursement approval, which the Company anticipates receiving in April, and the company will receive and ship a significant stocking order in advance of the commercial launch. The Aorfix endovascular stent graft with the AorFlex delivery system will be distributed by the company's exclusive partner in Japan, Medico's Hirata Inc. Aorfix is the first and only endovascular stent graft approved in Japan to treat AAAs in patients with aortic neck angulations up to 90 degrees, commonly considered to be challenging cases. Aorfix is also currently approved to treat patients with neck angles up to 90 degrees in the U.S. and Europe.

Lombard Medical, Inc. Presents at Barclays Global Healthcare Conference, Mar-12-2015 08:30 AM

Lombard Medical, Inc. Presents at Barclays Global Healthcare Conference, Mar-12-2015 08:30 AM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Simon Hubbert, Chief Executive Officer and Director.

Lombard Medical, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Reaffirms Revenue Guidance for 2015; Provides Revenue Guidance for the First Quarter of 2015

Lombard Medical, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, revenue was $4.8 million against $2.3 million last year. Operating loss was $8.9 million against $7 million last year. Loss before taxation was $8.9 million against $6.9 million last year. Loss for the period was $8.3 million, compared to $6 million last year. Basic and diluted loss per ordinary share from continuing operations was 51.2 cents against 53.4 cents last year. For the year, revenue was $13.3 million against $7 million last year. Operating loss was $36.1 million against $20.0 million last year. Loss before taxation was $36 million against $20.3 million last year. Loss for the period was $34.8 million, compared to $19.2 million last year. Basic and diluted loss per ordinary share from continuing operations was 238.7 cents against 214.0 cents last year. The increased net loss in the full year was principally due to on-going investments in U.S.-based operations, commercial infrastructure, additional direct sales people, product development activities, expenses of the NASDAQ initial public offering (IPO) and share-based compensation charges. Net cash outflow from operating activities was $34.2 million against $17.8 million last year. Purchase of property, plant and equipment was $1.5 million against $1.8 million last year. Purchase of intangible assets was $0.3 million against $2.1 million last year. The company reaffirmed that it expects to achieve revenue for 2015 of between $18 million and $20 million. This growth is expected to result from a more than doubling of the combined number of Aorfix procedures in the company's four large markets (U.S., Japan, UK and Germany) and pricing that remains stable in those markets. Due to the anticipated timing of Japan orders, total revenue for the first quarter of 2015 is anticipated to be between $3.0 million and $3.3 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVAR:US $4.00 USD +0.41

EVAR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $17.83 USD +0.39
CR Bard Inc $167.71 USD +1.05
Endologix Inc $16.52 USD +0.17
St Jude Medical Inc $65.82 USD +0.54
TriVascular Technologies Inc $10.31 USD +0.14
View Industry Companies
 

Industry Analysis

EVAR

Industry Average

Valuation EVAR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.4x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LOMBARD MEDICAL INC, please visit www.lombardmedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.